Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MP-3180 in Healthy Volunteers
NCT02098174Phase 1Completed
- Sponsor
- MediBeacon
- Start
- Nov 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relmapirazin in acute kidney injury (AKI) and chronic kidney disease (CKD), sponsored by MediBeacon. Primary endpoints: Total plasma clearance of MP-3180 and iohexol at 720 months, Renal clearance of MP-3180 and iohexol and 6 more. Started Nov 2013; status: completed.
02
Drugs
relmapirazin
03
Conditions
acute kidney injury (AKI)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02098174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098174.